arrow
C

Christopher Melani

national institutes of health
H指数:15
被引数:1,639

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A phase 1 trial of romidepsin, azacitidine, dexamethasone and lenalidomide in relapsed or refractory T-cell lymphoma

一項关于romidepsin、azacitidine、dexamethasone和lenalidomide在复发或难治性T细胞淋巴瘤中的1期临床试验

2026-02-160
OAAI
An Assessment of Kinase Selectivity; Enzyme Inhibition Kinetics and in Vitro Activity for Several Bruton Tyrosine Kinase (BTK) Inhibitors

对激酶选择性的评估;几种布鲁顿酪氨酸激酶(BTK)抑制剂的酶抑制动力学及体外活性

2025-11-180
OAAI
Multi- Component, Time- Course screening to develop combination cancer therapies based on synergistic toxicity

多组分,时程筛选,以开发基于协同毒性的联合癌症疗法

2024-11-250
PRE
Phase lb/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory and Treatment-Naive Mantle Cell Lymphoma: Preliminary Analysis of Safety, Efficacy, and Minimal Residual Disease

维奈克拉、依鲁替尼、泼尼松、奥滨尤妥珠单抗和来那度胺(ViPOR)在复发/难治性及初治套细胞淋巴瘤中的lb/2期研究:安全性、有效性和微小残留病初步分析

BLOOD
IF23.1
2024-11-050
PRE
Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma
2024-06-205
OAAI
Interferon alfa-2b in patients with low-grade lymphomatoid granulomatosis and chemotherapy with DA-EPOCH-R in patients with high-grade lymphomatoid granulomatosis: an open-label, single-centre, phase 2 trial
2023-05-015
PRE
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study
2018-12-01156
OAAI